United States securities and exchange commission logo





                             September 28, 2021

       Dipal Doshi
       President and Chief Executive Officer
       Entrada Therapeutics, Inc.
       6 Tide Street
       Boston, MA 02210

                                                        Re: Entrada
Therapeutics, Inc.
                                                            Amendment No. 1 to
Draft Registration Statement on Form S-1
                                                            Submitted September
15, 2021
                                                            CIK No. 0001689375

       Dear Mr. Doshi:

             We have reviewed your amended draft registration statement and
have the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       Amendment No. 1 to Draft Registration Statement on Form S-1, Submitted
September 15, 2021

       Prospectus Summary, page 1

   1.                                                   We note your response
to our prior comment number 1. To state that your EEV
                                                        therapeutic candidates
are efficient with respect to pharmacological effect and specific
                                                        with respect to the
engagement or involvement with a desired intracellular target of
                                                        interest implies that
your product candidates are effective. Please remove these statements
                                                        and all similar
statements as this determination is solely within the authority of the FDA
                                                        and comparable
regulatory bodies.
 Dipal Doshi
FirstName LastNameDipal
Entrada Therapeutics, Inc. Doshi
Comapany 28,
September NameEntrada
              2021       Therapeutics, Inc.
September
Page 2    28, 2021 Page 2
FirstName LastName
Business, page 112

2.       We note your response to our prior comment number 7. Comparisons to
other available
         treatments require head-to-head trials. Given these are not
head-to-head trials, please
         remove these statements.

       You may contact Jeanne Bennett at 202-551-3606 or Al Pavot at
202-551-3738 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Margaret Schwartz at 202-551-7153 or Celeste Murphy at 202-551-3257
with any other
questions.



                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Life
Sciences
cc:      Arthur R. McGivern, Esq.